Page last updated: 2024-09-03

norketamine and Parkinson Disease

norketamine has been researched along with Parkinson Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y	1

Other Studies

1 other study(ies) available for norketamine and Parkinson Disease

Article	Year
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. Psychopharmacology, 2020, Volume: 237, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Ketamine; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neostriatum; Neuroprotective Agents; Parkinson Disease; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase	2020

Article

Year

MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.

Psychopharmacology, 2020, Volume: 237, Issue:1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Ketamine; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neostriatum; Neuroprotective Agents; Parkinson Disease; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase

2020